Halozyme Thrp Stock Price, News & Analysis

Halozyme Therapeutics has revised its 2020 financial guidance following a global collaboration agreement with Horizon Therapeutics. The company increased its revenue forecast to $265 million to $275 million, up from $250 million to $260 million, indicating a year-over-year growth of 35% to 40%. Earnings per share projections also rose to $0.90 to $0.95, compared to the prior estimate of $0.80 to $0.85. This positive adjustment is attributed to ongoing revenue-generating activities in the fourth quarter.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be accessible on November 25 via the company’s investor relations website. Halozyme focuses on innovative biopharmaceutical solutions, primarily using its proprietary ENHANZE® technology, which enhances drug delivery and has positively impacted over 400,000 patients globally. The company partners with major pharmaceutical firms to develop new therapies, enhancing patient experiences and outcomes.

Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen Pharmaceutical submitted applications to both the FDA and EMA for the approval of DARZALEX FASPRO™ subcutaneous formulation. This treatment, aimed at relapsed or refractory multiple myeloma patients, allows administration in 3-5 minutes, vastly reducing the time from the traditional intravenous method. The application is backed by positive results from the Phase 3 APOLLO study suggesting longer progression-free survival compared to the standard treatment. The full study results will be presented at the ASH Annual Meeting on December 6, 2020.

Halozyme Therapeutics (NASDAQ: HALO) has announced that key studies sponsored by Janssen Research & Development will be presented at the American Society of Hematology (ASH) Annual Meeting from December 5-8, 2020. The Phase 3 APOLLO study will feature an oral presentation on December 6 at 3:00 p.m. ET, discussing subcutaneous daratumumab with pomalidomide and dexamethasone in multiple myeloma patients. The ANDROMEDA study results will be presented on December 7, also in an oral format, along with four additional poster presentations.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported robust financial results for Q3 2020, achieving a revenue of $65.3 million, up from $46.2 million year-over-year. The growth was driven by $32.0 million in collaboration revenue and a 44% rise in royalties. The company's net income was $36.2 million, marking a significant turnaround from a net loss in the prior year. Halozyme also raised its full-year revenue guidance to $250 million-$260 million, reflecting a projected 28-33% growth. The company has repurchased $312.4 million in shares, reinforcing its commitment to capital return.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host a webcast for its third-quarter 2020 financial results on November 2, 2020, at 4:30 p.m. ET. The call, led by CEO Dr. Helen Torley, follows the release of the financial results for the quarter ending September 30, 2020.

Investors can register through a provided link, with a replay available for two weeks post-call. Halozyme utilizes its ENHANZE® technology, enhancing drug delivery, to partner with major pharmaceutical firms and positively impact patient outcomes globally.

Halozyme Therapeutics (NASDAQ: HALO) has expanded its collaboration with argenx, adding exclusive access to its ENHANZE® drug delivery technology for three new targets. This brings the total to six targets under the agreement initiated in February 2019. argenx is advancing the development of its FcRn antagonist efgartigimod and has also nominated a complement inhibitor targeting C2. The collaboration aims to improve patient experiences by enabling subcutaneous delivery options for various therapies. Halozyme derives revenues through milestones and royalties from these partnerships.

Halozyme Therapeutics (NASDAQ: HALO) announced that Roche presented data from the Phase 1b study evaluating atezolizumab (Tecentriq) for subcutaneous use through Halozyme's ENHANZE technology at the ESMO Virtual Congress 2020. The study, involving 67 patients with advanced non-small cell lung cancer, showed that the subcutaneous formulation was well-tolerated and had similar exposure to the intravenous version. This supports further development in the Phase 3 study, potentially improving treatment efficiency by reducing administration time.